These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27722783)

  • 21. Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.
    Yamaguchi N; Miyamoto K; Murata T; Ishikawa E; Horiuchi T
    Artif Organs; 2016 Aug; 40(8):E158-66. PubMed ID: 27530675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Biocompatibility of Neutral Icodextrin Peritoneal Dialysis Fluid.
    Shimada S; Mori T; Koizumi K; Sato S; Oba-Yabana I; Ohsaki Y; Sato E; Naganuma E; Kurasawa N; Tsuchikawa M; Ito S
    Adv Perit Dial; 2016; 32():46-50. PubMed ID: 28988589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritoneal dialysis solutions.
    Wang T; Lindholm B
    Perit Dial Int; 2001; 21 Suppl 3():S89-95. PubMed ID: 11887870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidirectional approach to study peritoneal dialysis fluid biocompatibility in a chronic peritoneal dialysis model in the rat.
    Wieczorowska-Tobis K; Polubinska A; Wisniewska J; Pawlaczyk K; Kuzlan-Pawlaczyk M; Filas V; Breborowicz A; Oreopoulos DG
    Nephrol Dial Transplant; 2001 Mar; 16(3):655-6. PubMed ID: 11239060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of icodextrin-based dialysis solution on peritoneal leptin clearance.
    Opatrná S; Opatrný K; Racek J; Sefrna F
    Perit Dial Int; 2003; 23(1):89-91. PubMed ID: 12691516
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of peritoneal dialysis fluid biocompatibility on baroreflex sensitivity.
    John SG; Selby NM; McIntyre CW
    Kidney Int Suppl; 2008 Apr; (108):S119-24. PubMed ID: 18379534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis.
    Paniagua R; Orihuela O; Ventura MD; Avila-Díaz M; Cisneros A; Vicenté-Martínez M; Furlong MD; García-González Z; Villanueva D; Prado-Uribe MD; Alcántara G; Amato D
    Kidney Int Suppl; 2008 Apr; (108):S125-30. PubMed ID: 18379535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.
    Ahmad M; Shah H; Pliakogiannis T; Oreopoulos DG
    Int Urol Nephrol; 2007; 39(1):299-312. PubMed ID: 17004033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.
    Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi M; Tan SH; Voss D;
    J Am Soc Nephrol; 2012 Jun; 23(6):1097-107. PubMed ID: 22440906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane.
    Morelle J; Sow A; Fustin CA; Fillée C; Garcia-Lopez E; Lindholm B; Goffin E; Vandemaele F; Rippe B; Öberg CM; Devuyst O
    J Am Soc Nephrol; 2018 Jul; 29(7):1875-1886. PubMed ID: 29844208
    [No Abstract]   [Full Text] [Related]  

  • 31. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
    Tomo T
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S123-7. PubMed ID: 18552241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of using icodextrin as a starting therapy for peritoneal permeability].
    Fernández-Reyes MJ; Bajo MA; del Peso G; Olea T; Sánchez-Villanueva RL; González E; Heras M; Sánchez R; Selgas R
    Nefrologia; 2009; 29(2):130-5. PubMed ID: 19396318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent concepts in the molecular biology of the peritoneal membrane - implications for more biocompatible dialysis solutions.
    Mortier S; De Vriese AS; Lameire N
    Blood Purif; 2003; 21(1):14-23. PubMed ID: 12566656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium sieving in children.
    Rusthoven E; Krediet RT; Willems HL; Monnens LA; Schröder CH
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S141-2. PubMed ID: 16048281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten years after MIDAS: icodextrin lights and shadows.
    Amici G; Da Rin G; Agostini A; Velo S; Bocci C
    Contrib Nephrol; 2003; (140):76-81. PubMed ID: 12800346
    [No Abstract]   [Full Text] [Related]  

  • 36. Future of icodextrin as an osmotic agent in peritoneal dialysis.
    Pecoits-Filho R; Mujais S; Lindholm B
    Kidney Int Suppl; 2002 Oct; (81):S80-7. PubMed ID: 12230485
    [No Abstract]   [Full Text] [Related]  

  • 37. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
    Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
    Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of peritoneal leukocyte population with different dialysis fluids.
    Palomar R; López-Hoyos M; Morales P; Marín MJ; Alvarez L; Ruiz-Soto M; Rodrigo E; Fernández-Fresnedo G; Lm de Francisco A; Arias M
    Clin Nephrol; 2009 Aug; 72(2):137-42. PubMed ID: 19640371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peritoneal and Systemic Responses of Obese Type II Diabetic Rats to Chronic Exposure to a Hyperbranched Polyglycerol-Based Dialysis Solution.
    La Han B; Guan Q; Chafeeva I; Mendelson AA; da Roza G; Liggins R; Kizhakkedathu JN; Du C
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):494-503. PubMed ID: 29753311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of glucose in peritoneal dialysis: saint or sinner?
    Sitter T; Sauter M
    Perit Dial Int; 2005; 25(5):415-25. PubMed ID: 16178471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.